Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2019, Vol. 13 ›› Issue (11): 855-859. doi: 10.3877/cma.j.issn.1674-0785.2019.11.012

Special Issue:

• Basic Science Research • Previous Articles     Next Articles

Effect of diltiazem on myocardial ischemia-reperfusion injury in isolated rat hearts

Yunsheng Zhang1, Tianming Teng2, Wenjuan Zhang2,()   

  1. 1. Department of Cardiology, Tianjin Medical University General Hospital Airport Hospital, Tianjin 300308, China
    2. Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Received:2019-03-17 Online:2019-06-01 Published:2019-06-01
  • Contact: Wenjuan Zhang
  • About author:
    Corresponding author: Zhang Wenjuan, Email:

Abstract:

Objective

To investigate the effects of diltiazem on myocardial ischemia-reperfusion injury (MIRI) and the underlying mechanisms.

Methods

Wistar rats were randomly divided into three groups: normal group (N group), ischemia-reperfusion group (I-R group), diltiazem+ ischemia-reperfusion group (D/I-R group). The isolated rat hearts in different groups were given different perfusion treatments: The N group was given continuous perfusion of K-H liquid for 150 min; the I-R group was given stable perfusion of K-H liquid for 30 min followed by ligating the left anterior descending coronary artery for 30 min, and K-H liquid reperfusion for 90 min; the D/I-R group underwent reperfusion with diltiazem (5 μmo/L) for 15 min and reperfusion with K-H liquid for 75 min. Left ventricular cardiac function (LVDP), maximal rise/fall rate of left ventricular pressure (±dp/dtmax), reperfusion arrhythmia (RA) score, calculated myocardial infarct (MI) size, and ALDH2, Bcl-2, and BAX expression in the left ventricular apex were recorded in each group.

Results

The LVDP at 30 min and 45 min in the D/I-R group was significantly higher than that of the I-R group, respectively [(92.68±5.09) mmHg vs (75.77±5.33) mmHg, F=72.81, P=0.001; (90.39±4.29) mmHg vs (72.34±7.49) mmHg, F=51.92, P=0.001]. The ±dp/dtmax at 30 min and 45 min in the D/I-R group were significantly higher than that of the I-R group, respectively [+ dp/dtmax: (2885.45±286.47) mmHg vs (2063.64±105.57) mmHg, F=64.22, P=0.001 and (2712.73±236.52) mmHg vs (2053.64±92.33) mmHg, F=70.55, P=0.001; -dp/dtmax: (2214.55±104.63) mmHg vs (1710.91±217.97) mmHg, F=69.77, P=0.001 and (2119.09±84.43) mmHg vs (1544.55±207.72) mmHg, F=54.64, P=0.001, respectively]. The number of ventricular pre-contractions in the I-R group was significantly higher than that of the D/I-R group (P=0.001). The incidence of ventricular tachycardia, the time history of ventricular fibrillation, and the duration of ventricular tachycardia in the I-R group were also significantly higher than those of the D/I-R group (P=0.013, 0.049, and 0.001, respectively). The reperfusion arrhythmia score in the I-R group [5(3, 6), 57.36] was significantly higher than that of the D/I-R group [3(1, 4), 34.77] (P=0.001). Compared with the I-R group, the D/IR group had significantly smaller MI size [(55.51±1.43)% vs (17.01±1.13)%, P<0.01]. In the I-R group, the expression of mitochondrial ALDH2 was significantly reduced and that of Bcl-2 and Bax increased. Compared with the I-R group, the expression of mitochondrial ALDH2 was not significantly decreased in the D/IR group (P=0.11), while the expression of Bcl-2 and Bax was significantly increased. Compared with the I-R group, the D/I-R group had significantly increased Bcl-2/Bax ratio (0.44 vs 0.22, P=0.001).

Conclusion

Diltiazem reduces MIRI possibly by up-regulating the expression of mitochondrial Bcl-2 and down-regulating the expression of Bax. However, the therapeutic effect of diltiazem is not related with the gene and protein expression of mitochondrial ALDH2.

Key words: Myocardial, reperfusion injury, Diltiazem, Mitochondrial, Aldehyde dehydrogenase 2

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd